Respiratory syncytial virus (RSV) caused significant hospitalizations and severe outcomes in adults, especially those aged 75 ...

Regarding hospitalizations among immunocompetent older adults, vaccine effectiveness was 83% for the GSK vaccine and 73% for ...

The CDC recommends a single dose of any FDA-approved respiratory syncytial virus (RSV) vaccine for all adults ages 75 years ...

Cold, dry air is the ideal climate for viruses like the flu, phenomena and Respiratory Syncytial Virus (RSV), and these low ...

vaccination is associated with a lower RSV pneumonia risk and improved health outcomes in patients aged older than 60 years with inflammatory bowel disease (IBD), according to study results ...

RSV hospitalizations in US adults reached high levels pre-vaccine, especially impacting those 75 and older, underscoring the ...

Moderna said on Friday that Canada’s health regulator has approved its vaccine for respiratory syncytial virus (RSV) in adults 60 years and older, making it the country’s first authorized mRNA ...

Arexvy shows 62.9% efficacy against RSV-LRTD over three seasons in adults aged 60 and older. The vaccine demonstrates ... disease and 94.6% efficacy in patients with comorbidities.

Oct. 30—(StatePoint) Each year, up to 160,000 older adults living in the United States are hospitalized and as many as 10,000 die due to respiratory syncytial virus (RSV). RSV is a highly ...

RSV affects the nose, throat and lungs, causing substantial illness and death among older adults during these seasonal epidemics. In years prior to the availability of an RSV vaccine, an estimated ...

or RSV, in adults 60 years and older, making it the country's first authorized mRNA-based shot for the condition. Health Canada has approved the vaccine, mRESVIA, for prevention of lower ...